Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection by Lanara, Z. et al.
Lanara et al. Human Genomics 2013, 7:14
http://www.humgenomics.com/content/7/1/14PRIMARY RESEARCH Open AccessComparative study and meta-analysis of
meta-analysis studies for the correlation of
genomic markers with early cancer detection
Zoi Lanara1,2†, Efstathia Giannopoulou3†, Marta Fullen4, Evangelos Kostantinopoulos2, Jean-Christophe Nebel4,
Haralabos P Kalofonos3, George P Patrinos2 and Cristiana Pavlidis2*Abstract
A large number of common disorders, including cancer, have complex genetic traits, with multiple genetic and
environmental components contributing to susceptibility. A literature search revealed that even among several
meta-analyses, there were ambiguous results and conclusions. In the current study, we conducted a thorough
meta-analysis gathering the published meta-analysis studies previously reported to correlate any random effect or
predictive value of genome variations in certain genes for various types of cancer. The overall analysis was initially
aimed to result in associations (1) among genes which when mutated lead to different types of cancer (e.g.
common metabolic pathways) and (2) between groups of genes and types of cancer. We have meta-analysed 150
meta-analysis articles which included 4,474 studies, 2,452,510 cases and 3,091,626 controls (5,544,136 individuals in
total) including various racial groups and other population groups (native Americans, Latinos, Aborigines, etc.). Our
results were not only consistent with previously published literature but also depicted novel correlations of genes
with new cancer types. Our analysis revealed a total of 17 gene-disease pairs that are affected and generated gene/
disease clusters, many of which proved to be independent of the criteria used, which suggests that these clusters
are biologically meaningful.
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Cancer is the result of a complicated process that involves
the accumulation of both genetic and epigenetic alter-
ations in various genes [1]. The somatic genetic alterations
in cancer include point mutations, small insertion/deletion
events, translocations, copy number changes and loss of
heterozygosity [2]. These changes either augment the ac-
tion and/or expression of an oncoprotein or silence
tumour suppressor genes. Single-nucleotide polymorph-
ism (SNP) is the most common form of genetic variation
in the human genome. Although common SNPs for dis-
ease prediction are not ready for widespread use [3], re-
cent genome-wide association studies (GWASs) using
high-throughput techniques have identified regions of the* Correspondence: chpavlidou@upatras.gr
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reproduction in any medium, provided the orgenome that contain SNPs with alleles that are associated
with increased risk for cancer such as FGFR2 in breast
cancer [4-7].
The knowledge on gene mutations that predispose
tumour initiation or tumour development and progress
will give an advantage in cancer patients' treatment. Des-
pite the complexity and variability of cancer genome,
numerous studies have examined the correlation of gen-
ome variation with cancer development and progression
[8]. However, ambiguous results have been generated
from the attempt to link genome variants with cancer
prediction or detection. A literature search revealed that
even among several meta-analyses, there were unclear
results and conclusions.
We have, therefore, conducted a thorough meta-
analysis of meta-analysis studies previously reported to
correlate the random effect or predictive value of gen-
ome variations in certain genes for various types of can-
cer. The aim of the overall analysis was the detection ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.humgenomics.com/content/7/1/14correlations (1) among genes whose mutation might lead
to different types of cancer (e.g. common metabolic
pathways) and (2) between groups of genes and types of
cancer.
Methods
We performed a thorough field synopsis by studying
published meta-analysis studies involving the association
of various types of cancer with SNPs located in certain
genomic regions. For each published meta-analysis in-
cluded in our study, we also investigated the number of
patients (cases) and controls, date, type of study, study
group details (e.g. gender, race, age, etc.), measures in-
cluded, allele and genotype frequency and also the out-
come of each study, i.e. if there was an association or
not, the interactions noticed in each of these studies, etc.
We have meta-analysed 150 meta-analysis articles
(Additional file 1), which included 4,474 studies, 2,452,510
cases and 3,091,626 controls (5,544,136 individuals in
total). The meta-analyses that have been meta-analysed in-
cluded various racial groups, e.g. Caucasians, Far Eastern
populations (Asian, Chinese, Japanese, Korean, etc.),
African-American and other population groups (native
Americans, Latinos, Aborigines, etc.). Three types of
studies were included: (1) pooled analysis, (2) GWAS and
(2) other studies, e.g. search in published reports. Collected
data consisted of a list of genes, genomic variants and
diseases with a known genotype-phenotype association
(whether or not a given variation has an impact on suscep-
tibility to a given disease). The principle of our study was
to use data mining techniques to find groups (referred to
as clusters hereafter) of genes or diseases that behave simi-
larly according to related data. Such groupings will make it
possible to find different cancer types susceptible to similar
genotypes as well as different genes associated to similar
cancer types. Furthermore, our approach would facilitate
predicting whether susceptibility to one type of cancer may
be indicative of predisposition to another cancer type.
Moreover, the association between a group of genes and a
given phenotype may suggest that these genes interact or
belong to the same biochemical pathway. In order to allow
data mining analysis, genotype-phenotype associations had
to be classified within a fixed set of categories, i.e. yes/small
yes/may/no. Moreover, genes or diseases with fewer than
two entries were not considered in our analysis since their
clustering would not be meaningful.
Then, data were processed using a state-of-the-art gen-
eral purpose clustering tool, CLUTO [9]. Data analysis
consisted in finding the tightest and most reliable group-
ings. Since CLUTO offers a wide range of methods, and
many different scoring schemes can be used to estimate
similarity between genotypes or phenotypes, cluster reli-
ability was assessed by their robustness to clustering cri-
teria (details are provided in Additional file 1). As aconsequence, each putative association has been qualified
as either ‘highly consistent’ or ‘moderately consistent’. The
biological significance of those clusters was, first, evalu-
ated using the Search Tool for the Retrieval of Interacting
Genes/Proteins (STRING) [10,11], a biological database
and web resource of known and predicted protein-protein
interactions. The STRING database contains information
from numerous sources, including experimental data,
computational prediction methods and public text collec-
tions. It is widely accessible, and it is regularly updated.
Second, literature research was performed to complete
this initial evaluation.
Results and discussion
In this study, we performed a meta-analysis of published
meta-analysis studies to investigate possible correlations
among genes and SNPs and various types of cancer, as
well as among gene-gene and/or gene-environmental in-
teractions. Furthermore, an advanced literature research
was applied in order to evaluate our results obtained
from our meta-analysis. Our data were not only consist-
ent with previously published literature but we have also
depicted novel correlations of genes with new types of
cancer. Our analysis showed a total of ten cancer-related
genes that are affected (Table 1).
Correlation of SNPs' genes with various types of cancer
The association highlighted by our meta-analysis between
the CYP2E1 gene and colorectal cancer (CRC), head and
neck cancer (HNC) and liver cell carcinoma (LLC) is sup-
ported by published data [33-39,44,121]. An additional lit-
erature search to evaluate our initial results revealed novel
correlations of the gene combination CYP2E1 and GSTM1
with prostate cancer (PC) susceptibility, lung cancer (LC)
and bladder cancer (UBC) as shown in Table 2 [126-128].
A similar correlation was found in CRC using a knock-
down model [32,40,41]. Studies not only confirm the pos-
sibility of association between the CCND1 gene and breast
cancer (BC) [25] but also suggest involvement with squa-
mous cell carcinoma (SCC), oesophageal cancer (EC), oral
cancer (OC) and malignant glioma (MG), as arisen from
the interaction between the CCND1 and CCND3 genes
[26,122-124]. This is further corroborated in mouse model
studies that show association of CCND1 with BC
[25,27-31,153] and PC [125].
Moreover, as far as the ERCC2 is concerned along with
the association of ERCC1 gene with BC and LC which is
already confirmed [14-17,21,22], we have also identified
from our further literature search on humans the exist-
ence of an association with OC [26] and with HNC
[129-131]. There were no similar mouse studies that
could confirm or overrule our findings.
Our findings regarding the GSTP1 gene are confirmed
by the published literature [39,46-55]. Furthermore, we
Table 1 Summary of genes and SNPs identified by meta-analysis to be positively correlated with various cancers
Gene Cancer
type
SNPs References Supporting
referencesrs number Other name
ERCC2 BC rs13181 p.K715Q [12,13] [14-17]
ERCC2 BC rs1799793 p.D312N [12,18] [14-16]
ERCC2 LC rs13181 p.K751Q [19,20] [17,21,22]
ERCC2 LC rs1799793 p.D312N [23] [17,21,22]
CCND1 BC rs603965 c.870G>A [24] [25-31]
CYP2E1 CRC rs3813867 NA [32] [32-41]a
CYP2E1 HNC rs3813867 NA [42,43] [44]
CYP2E1 HNC rs6413432 NA [42] [44]
GSTP1 CRC rs1695 p.I105V [45] [39,46-55]
IL6 BC rs1800795 c.-174G>C [56,57]
MTHFR GC rs1801131 c.1298A>C [58] [59,60]b
MTHFR BC rs1801131 c.677C>T, c.1298A>C [61,62] [63,64]
SOD2 BC rs4880 p.V16A, p.A9V [62,65,66]
TGFB1 BC rs1800469 NA [67-69]
TGFB1 BC rs1800470 NA [67,70-73]
TGFB1 BC rs1982073 NA [74] [64,75-77]
TP53 BC rs1042522 p.R72P [78,79] [80-94]
TP53 UBC rs1042522 p.R72P [95] [96-100]
TP53 CRC rs1042522 p.R72P [78,101-103] [104-108]
TP53 CRC rs17878362 NA [78] [104-108]
TP53 EC rs1042522 p.R72P [109,110] [111]
TP53 LC rs1042522 p.R72P [78] [112-117]
TP53 LC rs17878362 NA [78] [112-117]
VEGFA BC rs3025039, rs699947 c.936C>T, c.-2578C>A [20,45,118,119] [120]
These findings are supported by the published literature. aFor a different SNP (rs1329149); bfor c.677C>T and c.1298A>C. NA not available.
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combination of GSTM1 and CYP1A1 [126,128,132,133].
Likewise, previous experimental evidence supports the
association we found between the MTHFR gene and BC,
basal cell carcinoma (BCC) [63,134] and gastric cancer
(GC) [59,60]. An association was also found between
MTHFR gene with other types of cancer, such as acute
lymphoblastic leukaemia (ALL) [135,136,154], LC [137],
UBC coming from interaction between CTH and
GSTM1 [138], CRC [139], non-Hodgkin's lymphoma
(NHL) [140,141], BC [64] and HNC [142]. Specifically,
in the case of NHL, the gene combination of MTHFR
and TYMS might influence the susceptibility to NHL
[140,141].
Concerning TGFB1, apart from the BC [64] that was
confirmed from the results of our further literature search
on humans and on mouse model [75,76], we have noticed
also the following associations with gastric dysplasia, LC,
pancreatic cancer (PanC) and BC [77,143-146]. Also, an as-
sociation of TGFB1 with CRC was found using a mouse
model [147].In addition for TP53 gene, we have observed in the re-
sults of our meta-analysis that it is associated with BC,
UBC, CRC, EC and LC [80-87,96-100,104-108,111-
113,149]. We have observed also that TP53 gene might be
associated with OC [88,148], too. Concerning the litera-
ture research on knockout mice, we have confirmed the
associations with BC [89-94] and LC [114-117], and we
have found also associations with ovarian cancer (OVCa)
[150], GC [151] and OC [152]. Moreover for the VEGFA
gene, based on further literature TGFB1 research, we have
confirmed the association with BC [120], but we had not
found any other evidence supporting the association with
other types of cancer.
Correlations between groups of genes and various types
of cancer
We have examined and confirmed the highly consistent
gene clustering results over further literature search via
STRING. Our search revealed additional types of cancer,
except from the types that we have studied in our meta-
analysis that seems to be related with pair of genes.
Table 2 Summary of genes and SNPs identified by further literature search as positively correlated with various cancers
Gene Cancer
type
SNPs References
rs number Other name
CCND1 OC rs603965 c.870G>A [26,122-124]
CCND1 PC rs603965 c.870G>A [125]
CYP2E1 PC NA NA [126]
CYP2E1 LC NA NA [127]
CYP2E1 UBC NA NA [128]
CYP2E1 OC NA NA [40]
ERCC2 OC rs1799793, rs13181 p.D312N, p.K751Q [23]
ERCC2 HNC rs1799793, rs13181 p.D312N, p.K751Q [129-131]
GSTP1 PC rs1695 p.I105V [126,128,132,133]
MTHFR BCC rs1801131 c.677C>T, c.1298A>C [134]
MTHFR ALL rs1801131 c.677C>T, c.1298A>C [59,135,136]
MTHFR LC rs1801131 c.677C>T, c.1298A>C [137]
MTHFR UBC rs1801131 c.677C>T, c.1298A>C [138]
MTHFR CC rs1801131 c.677C>T, c.1298A>C [139]
MTHFR NHL rs1801131 c.677C>T, c.1298A>C [140,141]
MTHFR HNC rs1801131 c.677C>T, c.1298A>C [142]
TGFB1 GC rs1982073 c.+29C>T [143]
TGFB1 LC rs1982073 c.+29C>T [144]
TGFB1 PC rs1982073 c.+29C>T [145]
TGFB1 PC rs1982073 c.+29C>T [146]
TGFB1 CRC rs1982073 c.+29C>T [147]
TP53 EmCa rs1042522/rs17878362 p.R72P [148]
TP53 PC rs1042522/rs17878362 p.R72P [114,149]
TP53 OVCa rs1042522/rs17878362 p.R72P [150]
TP53 GC rs1042522/rs17878362 p.R72P [151]
TP53 OC rs1042522/rs17878362 p.R72P [152]
NA not available.
Table 3 Putative gene-gene associations with various
cancer types
Gene
associations
Considered
phenotypes
Comments STRING
confirmation
Literature
confirmation
Gene
1
Gene
2
GSTP1 GSTM1 4 Binding
interaction
[Reference]:
study type
TGFB1 IL6 5 4 of 5
based on
‘yes’
MMP2 EGF 3 Based on
‘yes’
Activating
interaction
VEGFA IL1B 2 Activating
interaction
MMP9 IL8 4 Based on
‘may’
Activating
interaction
KEGG: same
process
MMP1 MMP3 5 Based on
‘may’
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GSTP1 and GSTM1 genes, activating interaction be-
tween MMP2 and EGF genes, between VEGFA and IL1B
genes and between MMP-9 and IL8 genes (Table 3). The
application of our machine learning method has high-
lighted that those pair of genes have similar association
profiles and, therefore, might be involved in the same
pathways. The genes that do not appear in the associa-
tions do not probably correlate with the presence of a
certain type of cancer.
First, in our meta-analyses, we observed that the inter-
action between IL6 and TGFB1 genes was associated to
the following types of cancer: BC, CRC, GC, LC and PC
as shown in Table 4. Although further literature search
on humans could not validate our highly consistent re-
sults, we discovered that these interactions are associ-
ated to additional types of cancer, such as HNC [187],
CRC [158], renal cancer (RC), small cell lung cancer
Table 4 Summary of gene-gene interactions and the corresponding SNPs in these genes
Gene
1
Gene
2
Cancer
type
SNP's gene 1 SNP's gene 2 References
(gene 1)
References
(gene 2)
Supporting
referencesrs number Other name rs number Other name
IL6 TGFB1 BC rs1800795 c.-174G>C rs1800469, rs1800470 c.-509C>T, p.T29C [56] [67-70,72-74] [155-157]
IL6 TGFB1 CRC rs1800795 c.-174G>C rs1800470 p.T29C [57] [71] [158]
IL6 TGFB1 GC rs1800795 c.-174G>C rs1800470 p.T29C [57] [71]
IL6 TGFB1 LC rs1800795 c.-174G>C rs1800470 p.T29C [57] [71]
IL6 TGFB1 PC rs1800795 c.-174G>C rs1800470 p.T29C [57] [71] [159]
MMP2 EGF LC rs2438650 c.-1306C>T rs4444903 c.61A>G [160] [161] [162]
MMP2 EGF BC rs2438650 c.-1306C>T rs4444903 c.61A>G [160] [161] [163-165]
MMP2 EGF GC rs2438650 c.-1306C>T rs4444903 c.61A>G [160] [161]
VEGFA IL1B BC rs3025039 c.936C>T rs114327 NA [166-169] [170] [171]
VEGFA IL1B BC rs699947 c.-2578C>A rs1143634 NA [172] [170] [171]
VEGFA IL1B BC NA NA rs16944 NA NA [170] [171]
VEGFA IL1B GC rs3025039 c.936C>T rs3087258 NA [45] [173]
VEGFA IL1B GC rs699947 c.-2578C>A NA IL1B-31-ami [95] [173]
MMP9 IL8 BC rs3918242 c.-1562C>T rs4073 c.-251A>T [160] [174] [171]
MMP9 IL8 CRC rs3918242 c.-1562C>T rs4073 c.-251A>T [160] [174]
MMP9 IL8 GC rs3918242 c.-1562C>T rs4073 c.-251A>T [160] [175]
MMP9 IL8 LC rs3918242 c.-1562C>T rs4073 c.-251A>T [160] [174]
MMP1 MMP3 BC rs1799750 c.-1607 1G>2G rs3025058 c.-1171 5A>6A [176] [176]
MMP1 MMP3 CRC rs1799750 c.-1607 1G>2G rs3025058 c.-1171 5A>6A [176] [176]
MMP1 MMP3 HNC rs1799750 c.-1607 1G>2G rs3025058 c.-1171 5A>6A [176] [176]
MMP1 MMP3 LC rs1799750 c.-1607 1G>2G rs3025058 c.-1171 5A>6A [176] [176] [177,178]
MMP1 MMP3 OVCa rs1799750 c.-1607 1G>2G rs3025058 c.-1171 5A>6A [176] [176]
GSTP1 GSTM1 CRC rs1695 p.I105V rs1065411 GSTM1 present/null [45] [179]
GSTP1 GSTM1 BC rs1695 p.I105V rs1065412 GSTM1 present/null [180] [181] [182,183]
GSTP1 GSTM1 OVCa rs1695 p.I105V rs1065413 GSTM1 present/null [184] [184]
GSTP1 GSTM1 UBC rs1695 p.I105V rs1065414 GSTM1 present/null [185] [186]
These were identified in our meta-analysis. Their correlation with various cancer types is also shown. NA not available.
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[193]. Additionally, regarding our further research on
the interaction between IL6 and TGFB1 genes on mouse
models, we have confirmed our initial results principally
for BC [155-157] and PC [159] and have noticed associa-
tions with epithelial cancer [194], skin tumour [195], LC
[196], OVCa and cervical cancer (CC) [197,198] and
HNSCC [199]. Second, we found that the interaction
between MMP-2 and EGF was associated with LC, BC
and GC (Table 4). Subsequently with a further literature
search, we confirmed the association with BC osteolysis
[163,164] and also found new associations with EC
[200], LC, RC and PC [162]. Furthermore, in some cases,
we have observed the association of the aforementioned
genes with OSCC [201]. In this study, EGF induced
MMP-1 expression that is required for type I collagen
degradation. In addition, MMP-1 is also associated with
human papillomavirus [202] and BC [165].Another interesting interaction that was revealed from
our analysis was between the VEGFA and IL1B genes that
were associated with BC and GC (Table 4). After proceed-
ing with a further literature search, we have not found simi-
lar results - except from one report [171] - but we have
identified additional associations with HNC, ALL, laryngeal
carcinoma and MM [203-206]. For MMP-9 and IL8 inter-
action, there was no study confirming our initial results for
BC, CRC and GC on neither humans nor mouse models.
We have observed though that there was evidence for an
association with nasopharyngeal carcinoma [171], LC
[177,178] and UBC [207]. Similarly, we could not find
any study that could support the interactions between
MMP-1 and MMP-3 and GSTP1 with GSTM1, although
two studies confirmed that GSTP1 and GSTM1 interac-
tions could be associated with BC [182,183] (Table 4).
Indications from further literature search on human
models revealed associations forMMP-1 andMMP-3 with
ABC
LC
CRCHNC
UBC
GCEC
OC
PC
BCC
ALL
CC
NHL EmCa OVCa
B
BC
LC
CRCHNC
UBC
GC
PC
OVCa
Figure 1 The distribution of various cancer types. According to
(A) the number of SNPs per cancer type and (B) the number of
genes or gene correlations per cancer type. By extrapolating the
data in Tables 1, 2, 3 and 4, it seems that the number of genome
variations and genes is profoundly bigger in BC, probably indicating
that this type of cancer is not a single disease but, most likely, a
spectrum of related disease states.
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skin [208], colorectal adenoma and RC [209,210], and for
GSTP1 and GSTM1, endometrial cancer (EmCa) [211],
LC [212], multiple myeloma (observed no significant asso-
ciation to prostatic adenoma and adenocarcinoma) [213],
PC [133,214], ALL [215], chronic myeloid leukaemia [216]
and PanC [217].We have then attempted to depict the various types of
cancers according to the number of SNPs and genes and/
or gene clusters found from our meta-analysis to be mean-
ingfully associated with certain cancer types. Our data in-
dicate that BC is correlated more often than the other
types of cancer both with the number of SNPs (Figure 1A)
as well as with the number of genes or gene clusters
(Figure 1B). This observation underlies the heterogeneity
of BC, indicating that it is, most likely, not a single disease
but a spectrum of related disease states.
Conclusions
In essence, our meta-analysis study generated clusters of
genes and diseases, many of which proved to be independ-
ent of the criteria used, which suggests that these clusters
are most likely biologically meaningful. Preliminary study
of some clusters and of our results shows that indeed
these genes interact. As regards the associations, with a
further literature analysis on human and mouse models,
we have also found meaningful gene associations related
to other cancer types not previously reported in the litera-
ture, an observation that warrants further investigation.Additional file
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